Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Treatment of bacterial sexually transmitted infections in Europe, gonorrhoea, Mycoplasma genitalium, and syphilis

  • Mitjà, Oriol|||0000-0003-3266-8868
  • Suñer, Clara|||0000-0003-2581-8864
  • Giacani, Lorenzo
  • Vall-Mayans, Martí|||0000-0001-9680-1010
  • Tiplica, George-Sorin
  • Ross, Jonathan D.C.
  • Bradshaw, Catriona S.
This review explores the therapeutic challenges of sexually transmitted infections (STI) in Europe, which include increasing antimicrobial resistance and limited progress in drug discovery. We primarily focus on gonorrhoea, Mycoplasma genitalium, and syphilis infections. For gonorrhoea with escalating resistance rates we explore the possibility of combining ceftriaxone with another antibiotic or using alternative antibiotics to mitigate resistance emergence, and we provide insights on the ongoing evaluation of new antimicrobials, like gepotidacin and zoliflodacin. In the case of M. genitalium, which exhibits high resistance rates to first and second-line treatments, we emphasize the importance of resistance-guided therapy in regions with elevated resistance levels, and highlight the limited alternative options, such as pristinamycin and minocycline. Furthermore, we address the challenges posed by syphilis, where the primary treatment consists of penicillin or doxycycline, with challenges arising in neurosyphilis, allergy, pregnancy, and supply shortages and discuss the ongoing evaluation of alternative antimicrobials (e.g., ceftriaxone, cefixime, linezolid). Our findings identify priority actions and provide concrete solutions for long-term effective management of STIs and antimicrobial resistance mitigation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Target Trial Emulation of the Modified Vaccinia Ankara-Bavarian Nordic Vaccine for Pre-Exposure Mpox Prevention in At-Risk Populations

  • Suñer, Clara|||0000-0003-2581-8864
  • Escrig-Sarreta, Roser
  • Galván-Casas, Cristina|||0000-0002-9662-9537
  • Matos, Eduardo|||0000-0002-3832-1657
  • Gabster, Amanda|||0000-0002-7712-0444
  • Wolff, Marcelo
  • Ouchi, Dan|||0000-0002-8630-152X
  • Alemany, Andrea|||0000-0001-8379-6857
  • Sánchez, Hugo
  • Huaman, Sandra
  • Bejarano, Dixennia
  • Carrés-Esteve, Lourdes
  • Santiago-Fernández, Cristina
  • Corral Rubio, Javier
  • Mendoza, Adrià
  • Rivero, Ángel|||0000-0003-2136-0702
  • Descalzo Jorro, Vicente
  • Orviz, Eva|||0000-0002-2684-3431
  • Martínez Riveros, Héctor|||0000-0003-3372-6134
  • Méndez-Boo, Leonardo|||0000-0002-9215-4378
  • Cabezas Peña, Carmen|||0000-0002-4291-0454
  • Arce-Arnáez, Araceli
  • Marks, Michael|||0000-0002-7585-4743
  • Mitjà, Oriol|||0000-0003-3266-8868
Background: The MVA-BN vaccine is considered effective for preventing mpox in key populations, based on observational studies, though no randomized trials have yet confirmed its effectiveness. Observational studies published to date rely on retrospective analyses of routine data, often missing information on relevant risk factors for mpox. Methods: Multi-country target trial emulation study with prospective data collection. Between 1 September 2022 and 15 June 2023, we recruited individuals eligible for mpox vaccination based on clinical history and exposure behaviors via healthcare centers and social venues in Spain, Peru, Panama, and Chile. Vaccinated individuals were paired with unvaccinated counterparts matched by mpox risk factors, country, recruitment date, and age. Follow-up continued via periodic surveys until 31 March 2024. The primary endpoint was symptomatic mpox occurrence ≥14 days post-vaccination. Results: The primary analysis included 1028 individuals (514 vaccinated, 514 unvaccinated) with a median follow-up time of 9.3 months (IQR 4.7-13.7). Mpox occurred in eight participants (0.8%): three vaccinated and five unvaccinated (HR 0.6; 95% CI 0.21-1.70). Adverse reactions were reported by 731 (49.6%) participants, predominantly skin reactions (703/1475; 47.7%), while systemic reactions occurred in 107 (7.3%). Long-lasting erythema at the injection site was reported in 450/1058 (42.5%) participants, persisting.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study

  • Tantalo, Lauren C.
  • Lieberman, Nicole A. P.
  • Pérez-Mañá, Clara
  • Suñer, Clara
  • Vall Mayans, Marti
  • Ubals, Maria
  • González-Beiras, Camila
  • Rodríguez-Gascón, Alicia
  • Canut, Andrés
  • González-Candelas, Fernando
  • Mueller, John
  • Tapia, Kenneth
  • Greninger, Alexander L.
  • Giacani, Lorenzo
  • Mitjà, Oriol
[Background]: The increasing incidence of syphilis and the limitations of first-line treatment with penicillin, particularly in neurosyphilis, neonatal syphilis, and pregnancy, highlight the need to expand the therapeutic repertoire for effective management of this disease. We assessed the in-vitro efficacy of 18 antibiotics from several classes on Treponema pallidum subspecies pallidum (T pallidum), the syphilis bacteria., [Methods]: Using the in-vitro culture system for T pallidum, we exposed the pathogen to a concentration range of each tested antibiotic. After a 7-day incubation, the treponemal burden was evaluated by quantitative PCR targeting the T pallidum tp0574 gene. The primary outcome was the minimum inhibitory concentration (MIC) at which the quantitative PCR values were not significantly higher than the inoculum wells. We also investigated the susceptibility of macrolide-resistant strains to high concentrations of azithromycin, and the possibility of developing resistance to linezolid, a proposed candidate for syphilis treatment., [Findings]: Amoxicillin, ceftriaxone, several oral cephalosporins, tedizolid, and dalbavancin exhibited anti-treponemal activity at concentrations achievable in human plasma following regular dosing regimens. The experiments revealed a MIC for amoxicillin at 0·02 mg/L, ceftriaxone at 0·0025 mg/L, cephalexin at 0·25 mg/L, cefetamet and cefixime at 0·0313 mg/L, cefuroxime at 0·0156 mg/L, tedizolid at 0·0625 mg/L, spectinomycin at 0·1 mg/L, and dalbavancin at 0·125 mg/L. The MIC for zoliflodacin and balofloxacin was 2 mg/L. Ertapenem, isoniazid, pyrazinamide, and metronidazole had either a poor or no effect. Azithromycin concentrations up to 2 mg/L (64 times the MIC) were ineffective against strains carrying mutations associated to macrolide resistance. Exposure to subtherapeutic doses of linezolid for 10 weeks did not induce phenotypic or genotypic resistance., [Interpretation]: Cephalosporins and oxazolidinones are potential candidates for expanding the current therapeutic repertoire for syphilis. Our findings warrant testing efficacy in animal models and, if successful, clinical assessment of efficacy., This project has been primarily funded by the European Research Council under the EU's Horizon 2020 research and innovation programme (grant agreement number 850450; grant holder OM). KT received support to conduct statistical analyses from the University of Washington under award numbers AI027757, AI144133, and AI027757 from the National Institutes of Health., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A new highly discriminatory typing scheme for Treponema pallidum reveals similar levels of genetic variability across lineages

  • Pla-Díaz, Marta
  • Giacani, Lorenzo
  • Tantalo, Lauren C.
  • Mitjà, Oriol
  • Arora, Natasha
  • González-Candelas, Fernando
Natasha Arora, Fernando González-Candelas, et al., The global resurgence of treponematoses, particularly syphilis, poses a growing public health challenge. Despite advances in sequencing technologies, obtaining complete Treponema pallidum genome sequences for epidemiological studies remains challenging due to clinical sampling and methodological constraints. There is, therefore, a need for rapid, cost-effective, and accessible typing methods. Based on the analysis of 121 T. pallidum genomes spanning all three subspecies (TPA, TPE, and TEN) from diverse regions, we selected seven highly variable genes (tp0136, tp0326, tp0548, tp0705, tp0858, tp0865, and tp1031) to form a new typing system, combined with analysis of macrolide resistance mutations in the 23S rRNA gene. The scheme was validated on 542 global T. pallidum samples, using either Sanger reads or whole genome sequence data, obtaining 82 sequence types (STs) among the 415 fully typed samples. Macrolide resistance mutations were frequently detected, highlighting the need for ongoing epidemiological surveillance. Phylogenetic analyses based on concatenated multilocus typing (MLST) loci recovered the expected subspecies and lineage structure. Consistently, almost all sequence types formed monophyletic groups, indicating strong concordance between MLST-based classification and whole-genome phylogenies. In addition, population genetic analyses revealed comparable levels of within-lineage diversity across subspecies and lineages, despite pronounced differences in geographic distribution, and identified distinct regional genetic clusters consistent with localized transmission dynamics. Importantly, the scheme employs a single-step PCR for all seven targets, facilitating implementation in standard laboratories and is publicly accessible through PubMLST. Overall, our novel MLST scheme offers a rapid, cost-effective tool to advance molecular epidemiology of T. pallidum, facilitate transmission and resistance tracking, and support global surveillance to strengthen public health interventions for syphilis and endemic treponematoses control., M.P.-D. has been funded by the FPU17/02367 program from the Spanish Ministerio de Educación. This research has been supported by grants BFU2017-89594-R, PID2021-127010OB-I00, and PID2024-155977OB-I00 from Spanish MICIN, CIPROM2021-053 from Generalitat Valenciana (to FGC), by the Swiss National Science Foundation: grant number 188963 “Towards the origins of syphilis” (to V.J.S.), and by the University of Zurich’s University Research Priority Program “Evolution in Action: from Genomes to Ecosystems” (to V.J.S.). Work in the Giacani lab was supported by the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Program (Grant agreement No. 850450 to O.M.), NIH U19 AI144133, and by the Open Philanthropy Pledge #8394150 (to L.G.). Some experiments conducted in Japan were supported by Grants-in-Aid for research on HIV/AIDS from the Ministry of Health, Labor and Welfare of Japan (grant number 20HB1003) to T.K. The work in the Czech Republic was partially funded by the National Institute of Virology and Bacteriology project (Programme EXCELES, ID Project No. LX22NPO5103, Funded by the European Union-Next Generation EU, recipient D.Š.), Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy of linezolid on Treponema pallidum, the syphilis agent, A preclinical study

  • Haynes, Austin M.
  • Giacani, Lorenzo
  • Mayans, Marti Vall
  • Ubals, Maria|||0000-0003-1394-197X
  • Nieto, Carles
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Quintó, Llorenç
  • Romeis, Emily
  • Mitjà, Oriol|||0000-0003-3266-8868
Penicillin G, the current standard treatment for syphilis, has important drawbacks, but virtually no preclinical or clinical studies have been performed to identify viable alternatives. We tested, both in vitro and in vivo, three marketed antibiotics with adequate pharmacological properties to treat syphilis. We used an in vitro culturing system of T. pallidum to perform drug susceptibility testing and applied quantitative PCR targeting the tp0574 gene to measure bacterial growth. To confirm in vivo efficacy, fifteen rabbits were infected intradermally with T. pallidum at eight sites each and randomly allocated to an experimental treatment (linezolid, moxifloxacin, clofazimine) or a control arm (benzathine penicillin G [BPG], untreated). The primary outcome was treatment efficacy defined as the time to lesion healing measured from the date of treatment start. Secondary outcomes were absence of treponemes or treponemal mRNA in injection sites, absence of seroconversion, and cerebrospinal fluid (CSF) abnormalities and negative rabbit infectivity tests (RIT). Linezolid showed in vitro bactericidal activity at concentrations of 0.5 µg/mL or higher. When administered orally to experimentally infected rabbits, it induced healing of early lesions at a time similar to BPG (hazard ratio 3.84; 95% CI 2.05-7.17; p < 0.0001 compared to untreated controls). In linezolid-treated animals, dark-field microscopy and qPCR assessment showed no presence of treponemes after day 3 post-treatment start, serologic test did not convert to positive, CSF had no abnormalities, and RIT was negative. Moxifloxacin and clofazimine failed to inhibit bacterial growth in vitro and could not cure the infection in the rabbit model. Linezolid, a low-cost oxazolidinone, has in vitro and in vivo activity against T. pallidum, with efficacy similar to BPG in treating treponemal lesions in the animal model. Our findings warrant further research to assess the efficacy of linezolid as an alternative to penicillin G to treat syphilis in human clinical trials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Antimicrobial susceptibility of Treponema pallidum subspecies pallidum, an in-vitro study

  • Tantalo, Lauren C
  • Lieberman, Nicole A P
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Suñer, Clara|||0000-0003-2581-8864
  • Vall Mayans, Marti
  • Ubals, Maria|||0000-0003-1394-197X
  • González-Beiras, Camila|||0000-0001-6617-0748
  • Rodríguez-Gascón, Alicia
  • Canut-Blasco, Andrés
  • González-Candelas, Fernando|||0000-0002-0879-5798
  • Mueller, John
  • Tapia, Kenneth
  • Greninger, Alexander L
  • Giacani, Lorenzo
  • Mitjà, Oriol|||0000-0003-3266-8868
The increasing incidence of syphilis and the limitations of first-line treatment with penicillin, particularly in neurosyphilis, neonatal syphilis, and pregnancy, highlight the need to expand the therapeutic repertoire for effective management of this disease. We assessed the in-vitro efficacy of 18 antibiotics from several classes on Treponema pallidum subspecies pallidum (T pallidum), the syphilis bacteria. Using the in-vitro culture system for T pallidum, we exposed the pathogen to a concentration range of each tested antibiotic. After a 7-day incubation, the treponemal burden was evaluated by quantitative PCR targeting the T pallidum tp0574 gene. The primary outcome was the minimum inhibitory concentration (MIC) at which the quantitative PCR values were not significantly higher than the inoculum wells. We also investigated the susceptibility of macrolide-resistant strains to high concentrations of azithromycin, and the possibility of developing resistance to linezolid, a proposed candidate for syphilis treatment. Amoxicillin, ceftriaxone, several oral cephalosporins, tedizolid, and dalbavancin exhibited anti-treponemal activity at concentrations achievable in human plasma following regular dosing regimens. The experiments revealed a MIC for amoxicillin at 0·02 mg/L, ceftriaxone at 0·0025 mg/L, cephalexin at 0·25 mg/L, cefetamet and cefixime at 0·0313 mg/L, cefuroxime at 0·0156 mg/L, tedizolid at 0·0625 mg/L, spectinomycin at 0·1 mg/L, and dalbavancin at 0·125 mg/L. The MIC for zoliflodacin and balofloxacin was 2 mg/L. Ertapenem, isoniazid, pyrazinamide, and metronidazole had either a poor or no effect. Azithromycin concentrations up to 2 mg/L (64 times the MIC) were ineffective against strains carrying mutations associated to macrolide resistance. Exposure to subtherapeutic doses of linezolid for 10 weeks did not induce phenotypic or genotypic resistance. Cephalosporins and oxazolidinones are potential candidates for expanding the current therapeutic repertoire for syphilis. Our findings warrant testing efficacy in animal models and, if successful, clinical assessment of efficacy. European Research Council.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain, a prospective, open-label, non-inferiority, randomised controlled trial

  • Ubals, Maria|||0000-0003-1394-197X
  • Arando, Maider|||0000-0003-2020-4193
  • Rivero, Ángel|||0000-0003-2136-0702
  • Mendoza, Adrià
  • Descalzo Jorro, Vicente
  • Ouchi, Dan|||0000-0002-8630-152X
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Álvarez, Marlene|||0000-0002-5922-7811
  • Alemany, Andrea|||0000-0001-8379-6857
  • Hoyos-Mallecot, Yannick
  • Nunley, Ethan
  • Lieberman, Nicole P.
  • Greninger, Alexander L.
  • Galván-Casas, Cristina|||0000-0002-9662-9537
  • Suñer, Clara|||0000-0003-2581-8864
  • G-Beiras, Camila
  • Paredes, Roger|||0000-0002-6553-691X
  • Rodríguez-Gascón, Alicia
  • Canut-Blasco, Andrés
  • García-Patos Briones, Vicente|||0000-0003-1654-6035
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Marks, Michael|||0000-0002-7585-4743
  • Giacani, Lorenzo
  • Vall-Mayans, Martí|||0000-0001-9680-1010
  • Mitjà, Oriol|||0000-0003-3266-8868
  • Nadal-Barón, Patricia|||0000-0002-2656-2656
Background: Management of syphilis, a sexually transmitted infection (STI) with increasing incidence, is challenged by drug shortages, scarcity of randomised trial data, an absence of non-penicillin alternatives for pregnant women with penicillin allergy (other than desensitisation), extended parenteral administration for neurosyphilis and congenital syphilis, and macrolide resistance. Linezolid was shown to be active against Treponema pallidum, the causative agent of syphilis, in vitro and in the rabbit model. We aimed to assess the efficacy of linezolid for treating early syphilis in adults compared with the standard of care benzathine penicillin G (BPG). Methods: We did a multicentre, open-label, non-inferiority, randomised controlled trial to assess the efficacy of linezolid for treating early syphilis compared with BPG. We recruited participants with serological or molecular confirmation of syphilis (either primary, secondary, or early latent) at one STI unit in a public hospital and two STI community clinics in Catalonia (Spain). Participants were randomly allocated in a 1:1 ratio using a computer-generated block randomisation list with six participants per block, to receive either oral linezolid (600 mg once per day for 5 days) or intramuscular BPG (single dose of 2·4 million international units) and were assessed for signs and symptoms (once per week until week 6 and at week 12, week 24, and week 48) and reagin titres of non-treponemal antibodies (week 12, week 24, and week 48). The primary endpoint was treatment response, assessed using a composite endpoint that included clinical response, serological response, and absence of relapse. Clinical response was assessed at 2 weeks for primary syphilis and at 6 weeks for secondary syphilis following treatment initiation. Serological cure was defined as a four-fold decline in rapid plasma reagin titre or seroreversion at any of the 12-week, 24-week, or 48-week timepoints. The absence of relapse was defined as the presence of different molecular sequence types of T pallidum in recurrent syphilis. Non-inferiority was shown if the lower limit of the two-sided 95% CI for the difference in rates of treatment response was higher than -10%. The primary analysis was done in the per-protocol population. The trial is registered at ClinicalTrials.gov (NCT05069974) and was stopped for futility after interim analysis. Findings: Between Oct 20, 2021, and Sept 15, 2022, 62 patients were assessed for eligibility, and 59 were randomly assigned to linezolid (n=29) or BPG (n=30). In the per-protocol population, after 48 weeks' follow-up, 19 (70%) of 27 participants (95% CI 49·8 to 86·2) in the linezolid group had responded to treatment and 28 (100%) of 28 participants (87·7 to 100·0) in the BPG group (treatment difference -29·6, 95% CI -50·5 to -8·8), which did not meet the non-inferiority criterion. The number of drug-related adverse events (all mild or moderate) was similar in both treatment groups (five [17%] of 29, 95% CI 5·8 to 35·8 in the linezolid group vs five [17%] of 30, 5·6 to 34·7, in the BPG group). No serious adverse events were reported during follow-up. Interpretation: The efficacy of linezolid at a daily dose of 600 mg for 5 days did not meet the non-inferiority criteria compared with BPG and, as a result, this treatment regimen should not be used to treat patients with early syphilis. Funding: European Research Council and Fondo de Investigaciones Sanitarias.